Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2017

  • ID: 4396656
  • Clinical Trials
  • Region: Global
  • 76 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Plc
  • Novartis AG
  • Retrophin Inc
  • MORE
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2017" provides an overview of Focal Segmental Glomerulosclerosis (FSGS) clinical trials scenario. This report provides top line data relating to the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Mallinckrodt Plc
  • Novartis AG
  • Retrophin Inc
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Focal Segmental Glomerulosclerosis (FSGS)
Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlights Potential for CCR2 Inhibition in Focal Segmental Glomerulosclerosis
May 25, 2017: Retrophin Announces Presentations On Late-Stage Clinical Development Program Sparsentan at Upcoming Medical Congress
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Source

List of Tables
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials by Region, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, North America, Top Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials by Region (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Focal Segmental Glomerulosclerosis (FSGS) to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ligand Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Variant Pharmaceuticals Inc
  • Shire Plc
  • Sanofi
  • Retrophin Inc
  • Novartis AG
  • Mallinckrodt Plc
  • Astellas Pharma Inc
  • AstraZeneca Plc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll